The invention concerns herbal compositions which improve lactation of farmed livestock comprising an effective amount of an extract and/or at least one bioactive fraction or powder from herbs such as Asparagus, Gossypium, Foeniculum, Lepidium, Chlorophytum, Ipomoea, Withania, Leptadenia and optionally dicalcium phosphate, chelated minerals and/or mineral mixture.

The invention concerns herbal compositions which improve lactation of farmed livestock comprising an effective amount of an extract and/or at least one bioactive fraction or powder from herbs such as Asparagus, Gossypium, Foeniculum, Lepidium, Chlorophytum, Ipomoea, Withania, Leptadenia and optionally dicalcium phosphate, chelated minerals and/or mineral mixture.

Methods and compositions for potentiating the effect of an opioid analgesic in a patient undergoing or planning to undergo opioid analgesic therapy using a potentiating amount of iboga alkaloid or pharmaceutically acceptable salt and/or solvate thereof that does not prolong the patient's QT interval by more than about 50 milliseconds.

Methods and compositions for potentiating the effect of an opioid analgesic in a patient undergoing or planning to undergo opioid analgesic therapy using a potentiating amount of iboga alkaloid or pharmaceutically acceptable salt and/or solvate thereof that does not prolong the patient's QT interval by more than about 50 milliseconds.

Methods and compositions for potentiating the effect of an opioid analgesic in a patient undergoing or planning to undergo opioid analgesic therapy using a potentiating amount of iboga alkaloid or pharmaceutically acceptable salt and/or solvate thereof that does not prolong the patient's QT interval by more than about 50 milliseconds.

A method of isolating at least one phenanthroindolizidine alkaloid, in particular with telomerase inhibitory activity, from Tylophora atrofolliculata is used to isolate and obtain for example about six to eight phenanthroindolizidine alkaloids, including at least four new phenanthroindolizidine alkaloids which have not been previously isolated. Experimental tests confirmed an exceptional telomerase inhibitory activity of the phenanthroindolizidine alkaloids isolated. A pharmaceutical composition includes at least one phenanthroindolizidine alkaloid and at least one pharmaceutical tolerable excipient. Still further, a method of treating a subject suffering from cancer includes administering at least one phenanthroindolizidine alkaloid isolated from Tylophora atrofolliculata. Also, a method of treating a subject suffering from cancer includes administering to the subject at least one phenanthroindolizidine alkaloid having certain formula.

A method of treating viral infection, such as viral infection caused by a virus of the Coronaviridae family, is provided. A composition having at least oleandrin is used to treat viral infection.

A method of isolating at least one phenanthroindolizidine alkaloid, in particular with HIF-1 inhibitory activity, from Tylophora atrofolliculata is used to isolate and obtain for example about 22 phenanthroindolizidine alkaloids, including at least 11 new phenanthroindolizidine alkaloids which have not been previously isolated. Experimental tests confirmed an exceptional HIF-1 inhibitory activity of the phenanthroindolizidine alkaloids isolated. A pharmaceutical composition includes at least one phenanthroindolizidine alkaloid and at least one pharmaceutical tolerable excipient. A method of treating a subject suffering from cancer includes administering at least one phenanthroindolizidine alkaloid isolated from Tylophora atrofolliculata. A method of treating a subject suffering from cancer includes administering at least one phenanthroindolizidine alkaloid to the subject.

A method of isolating at least one phenanthroindolizidine alkaloid, in particular with HIF-1 inhibitory activity, from Tylophora atrofolliculata is used to isolate and obtain for example about 22 phenanthroindolizidine alkaloids, including at least 11 new phenanthroindolizidine alkaloids which have not been previously isolated. Experimental tests confirmed an exceptional HIF-1 inhibitory activity of the phenanthroindolizidine alkaloids isolated. A pharmaceutical composition includes at least one phenanthroindolizidine alkaloid and at least one pharmaceutical tolerable excipient. A method of treating a subject suffering from cancer includes administering at least one phenanthroindolizidine alkaloid isolated from Tylophora atrofolliculata. A method of treating a subject suffering from cancer includes administering at least one phenanthroindolizidine alkaloid to the subject.

A method of treating HTLV-1 virus infection. A composition having at least one cardiac glycoside is used to treat viral infection. The composition can further include at least one triterpene. Alternatively, the composition comprises the combination of at least one cardiac glycoside and at least one, at least two, or at least three triterpenes.